Two important biotech legal rulings:

First the Federal Circuit Court of Appeals on May 30 issued a ruling re-affirming its earlier vacated decision that Eli Lilly's patent on Prozac is invalid for double patenting. The court's earlier decision had been vacated and this ruling invalidates the patent on similar grounds but with different analysis. Barr Laboratories the opposing party plans to offer generic Prozac as early as August.Second, the European Patent Office in Munich invalidated Hoffman-La Roche's patent on Taq polymerase as obvious and lacking novelty based upon prior art. This ruling is consistent with US court rulings invalidating the same patent in the US for fraud on the PTO.

Return to MVS News and Events

Connect with MVS

Enter your name and email address to recieve the latest news and updates from us and our attorneys.

Subscribe to: MVS Newsletter

Subscribe to: Filewrapper® Blog Updates

  I have read and agree to the terms and conditions of McKee, Voorhees & Sease, P.L.C.